Abstract: To realize effective cancer immunotherapy, Ding et al. constructed a structurally well-defined DNA-based nanodevice to quantitatively assemble cancer cell-specific antigen and multiple adjuvants as a cancer vaccine. This nanodevice vaccine can efficiently accumulate in the draining lymph nodes and respond to the endosomal acidic environment of dendritic cells to release the antigen and adjuvants. These active payloads stimulate dendritic cells maturation and antigen presentation to elicit a robust, antigen-specific cytotoxic T-lymphocyte response to kill cancer cells. This work has been published online in the Nature Materials on Sept.7, 2020.